Pfizer and biontech conclude phase 3 study of covid-19 vaccine candidate, meeting all primary efficacy endpoints

New york and mainz, germany, november 18, 2020 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced that, after conducting the final efficacy analysis in their ongoing phase 3 study, their mrna-based covid-19 vaccine candidate, bnt162b2, met all of the study's primary efficacy endpoints. analysis of the data indicates a vaccine efficacy rate of 95% (p
BNTX Ratings Summary
BNTX Quant Ranking